| Literature DB >> 31178720 |
Priyanka Saha1, Anupam Das Talukdar1, Rajat Nath1, Satyajit D Sarker2, Lutfun Nahar2, Jagajjit Sahu3, Manabendra Dutta Choudhury1.
Abstract
The liver is not only involved in metabolism and detoxification, but also participate in innate immune function and thus exposed to frequent target Thus, they are the frequent target of physical injury. Interestingly, liver has the unique ability to regenerate and completely recoup from most acute, non-iterative situation. However, multiple conditions, including viral hepatitis, non-alcoholic fatty liver disease, long term alcohol abuse and chronic use of medications can cause persistent injury in which regenerative capacity eventually becomes dysfunctional resulting in hepatic scaring and cirrhosis. Despite the recent therapeutic advances and significant development of modern medicine, hepatic diseases remain a health problem worldwide. Thus, the search for the new therapeutic agents to treat liver disease is still in demand. Many synthetic drugs have been demonstrated to be strong radical scavengers, but they are also carcinogenic and cause liver damage. Present day various hepatic problems are encountered with number of synthetic and plant based drugs. Nexavar (sorafenib) is a chemotherapeutic medication used to treat advanced renal cell carcinoma associated with several side effects. There are a few effective varieties of herbal preparation like Liv-52, silymarin and Stronger neomin phages (SNMC) against hepatic complications. Plants are the huge repository of bioactive secondary metabolites viz; phenol, flavonoid, alkaloid etc. In this review we will try to present exclusive study on phenolics with its mode of action mitigating liver associated complications. And also its future prospects as new drug lead.Entities:
Keywords: gene network; hepatoprotection; in silico analysis; liver disease; mechanism; natural product; phenolics
Year: 2019 PMID: 31178720 PMCID: PMC6543890 DOI: 10.3389/fphar.2019.00509
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Statistical representation of mortality (in percentage) from various diseases in human (Finkelstein et al., 2012).
Figure 2Occurrence and prevalence of various liver diseases worldwide.
Figure 3Structures of various groups of phenolic compounds (Hussain, 2016; Mandal et al., 2017; Xi et al., 2018).
Figure 4Flowchart showing various descendants of the phenolic groups.
Figure 5Structures of some bioactive phenolics acting as hepatoprotective compounds.
Figure 6Structures of some bioactive phenolics acting as hepatoprotective compounds.
Figure 7Metabolism of phenols in the living system. The metabolism of the dietary components rich in phenols is easily absorbed by various part of the animal body where the small intestine process and deviates the potent part to hepatic cells and remains are hydrolysed in colon and excreted via feces. Simultaneously, a part of it is methylated in kidney through liver and the last remains are excreted through urination. The red arrows mark is used to show the various route of metabolism of phenols.
Figure 8Detailed Mechanism of generation of hepatotoxicity. When the elicitors like alcohol, CCl4, enter the cell membrane they instigate various metabolic reactions activating the CYP systems viz; activating the endogenous glutathione enzyme, hydrogen peroxide. Formation of the reactive oxygen species are responsible for the lipid peroxidation reaction. A conjugation reaction takes place alongside this resulting in the deterioration in the ATP levels and elevation in the caspases levels. This clinical manifestation leads to the building up of hepatotoxicity and induces apoptosis. The nucleus also takes part in such build up by upregulating various transcription factors associated with inflammation. The adhesion molecules present in the cell membrane further create a hepatic fibrotic response by coupling with various reactive oxygen species. The activated Kupffer cells, on the other hand, further activate the prostaglandin by COX-2 and thus increases the cytokines level in the blood. These reactions are catalyzed by arachidonic acid. Such atrocities give rise to associated diseases with inflammation and further fibrogenesis. Hepatic necrosis is another condition imparted by the activated neutrophil which, though inactive during a normal state, increase in number when the cytokine level increases in the blood. The fatal condition, hepatic cirrhosis, is also encountered from hepatotoxicity, which is the additive effect of the prolonged inflammation and interaction with the ROS generation.
Figure 9Alcohol mediated Hepatotoxicity. Hepatotoxicity caused by increased production of ROS; due to alcohol damages antioxidant defenses and mitochondrial function as well as structure. It leads to liver inflammation, fibrosis and steatosis. Cellular responses, which are sturdily involved in Kupffer cell may also activated due to action of ROS which contribute to an increase of inflammatory responses, resulting liver injury. Furthermore, activated Kupffer cells release ROS and cytokines that are crucial for HSC activation and inducing the pro-fibrogenic pathway.
Figure 10Protective effect of phenols in various metabolic pathways in liver diseases. The upward arrow indicating upregulation and down arrow indicating downregulation of the enzymes.
Figure 11Gene networking showing hepatotoxicity mediated gene expression and subsequent mode of action of various natural products. This network was generated by a software Cytoscape version 3.6.1.
Figure 12Gene-modeling showing various hepatic diseases and associated genes with it. A tool named Circus on shiny Circos server generated this image. The blue band is showing various genes responsible for pathophysiological conditions, the green showing various hepatic complications and the red band shows the bioactive natural compounds possessive hepatoprotective activity. Various shades indicating the degree of relatedness between the various bands.
List of a few potent natural phenolics and their mode of action imparting hepatoprotective activity.
| 1 | Apigenin | Flavone | Hepatic ischemia/reperfusion | Up regulating BCL-2 levels | (Tsaroucha et al., | |
| 2. | Caffeic acid | Phenolic acids | Diabetic Liver injury | Lipid peroxidation and antioxidant enzymes | (Yilmaz et al., | |
| 3. | Catechin | Flavonols | Hepatic tissue injury | Antifibrotic and antioxidative | (Kobayashi et al., | |
| 4. | Curcumin | Curcuminoids | Non-alcoholic steatohepatitis | Immunomodulatory | (Nafisi et al., | |
| 5. | Epicatechin | Flavonoids | Diabetic liver injury | Lipid peroxidation and antioxidant enzymes Effects of (–)epicatechin, a flavonoid on lipid peroxidation and antioxidants streptozotocin-induced diabetic liver, kidney and heart. | (Terao et al., | |
| 6. | Ferulic acid | Phenolic acids | Carbon tetrachloride (CCl4)-induced acute liver injury | Antioxidant, anticancer, and anti-inflammatory | (Kim et al., | |
| 7. | Hyperoside | Flavonol | Liver injury | Enhancement of APAP clearance | (Choi et al., | |
| 8. | Icariin | Prenylated flavonol glycoside (Flavonoid) | Hepatic fibrosis | Anti-angiogenic and anti-autophagic | (Algandaby et al., | |
| 9. | Magnolol | Neo-lignan | Immune-related liver fibrosis | Anti-inflammatory and antioxidant effects | (Ogata et al., | |
| 10. | Morin | Flavonoid | Hepatic fibrosis | Suppressing canonical NF-κBsignaling. | (Sivaramakrishnan and Niranjali Devaraj, | |
| 11. | Naringenin | Flavanone | Hepatic inflammation | Activation of an Nrf2-mediated pathway | (Totta et al., | |
| 12. | Resveratrol | Stilbenoid | Alcoholic fatty liver | Inhibition of sirtuin 1 (SIRT1) and AMP-activated kinase (AMPK) | (Frémont, | |
| 13. | Wogonoside | Flavonoid | Hepatic fibrosis | Antifibrotic | (Yang et al., |
Table showing various hepatic diseases and various genes and metabolites associated with it.
| Amentoflavone | Microsomal lipid peroxidation | Fatty liver disease | COX-2 | Inflammatory mediators | Inhibition | AP-1(downregulation) | (Arannilewa et al., |
| Baicalein | Hepatic apoptosis, inflammatory liver injury | Acute liver apoptosis | IκBα, ERK and JNK | Inflammatory mediators | Downregulation | NF-κβ (down regulate) | (Liu et al., |
| Caffeic acid | Inflammatory liver injury | Acute liver failure | c-FLIPL, XIAP and cIAP2 proteins | Apoptotic protein | Activation | NF-κβ (down regulate) | (Shi et al., |
| Inflammatory liver injury | Acute liver failure | c-FLIPL, XIAP and cIAP2 proteins | Apoptotic protein | Activation | TNF-α (down regulate) | (Wang et al., | |
| Hepatic lipid peroxidation | Alcoholic fatty liver disease (AFLD) | Glutathione reductase(GSH) | Antioxidant enzymes | Increase | Microsomal ethanol-oxidizing system(increase) | (Chu et al., | |
| Clofibrate | Hepatic excessive proliferation | HCV-mediated hepatocellular carcinoma (HCC) | Cyp4a10 and Cyp4a14 | mRNA expression of factors | Increase | Acox1, Ech1, and Ehhadh (increased) Lipe and Pnpla2 (increased) | (Moody and Reddy, |
| Galangin | Microsomal lipid peroxidation | Fatty liver disease | COX-2 and iNOS | Inflammatory mediators | 0 inhibition | NF-κB (downregulation) | (Ren et al., |
| Gardenin D | Microsomal lipid peroxidation | Fatty liver disease | COX-2 | inflammatory mediators | Inhibition | AP-1(downregulation | (Toppo et al., |
| Glabridin | Chronic inflammatory liver disease | Acute or chronic hepatitis and | PPARγ (peroxisome proliferator-activated receptor gamma) | (Thakur and Raj, | |||
| Chronic inflammatory liver disease | Hepatic steatosis | CCAAT enhancer binding protein alpha (CEBPα) | Inflammatory mediators | Downregulation | Phosphoenol pyruvate carboxykinase and glucose 6-phosphatase (downregulate) | (Namazi et al., | |
| Cytochrome c, | (Lin et al., | ||||||
| Hispidulin | Hepatic lipid peroxidation | Alcoholic fatty liver disease (AFLD) | Glutathione reductase(GSH) | Antioxidant enzymes | Increase | Microsomal ethanol-oxidizing system(increase) | (Wu and Xu, |
| Icariin | Hepatic excessive proliferation | HCV-mediated hepatocellular carcinoma (HCC) | PPARα | mRNA expression of factors | Inhibition | Cpt1a, Acat1, Acad1 and Hmgcs2 (increased) | (Lee et al., |
| Kaempferol | Fatty liver diseases | Liver fibrosis | iNOS, COX-2 and CRP protein level | Inflammatory mediators | Downregulation | NF-κβ (down regulate) | (García-Mediavilla et al., |
| Fatty liver diseases | Liver fibrosis | (IRS-1) (IKKα) and (IKKβ). | Inflammatory mediators | Downregulation | kappa-β (NF-κB), (TNF-α) and (IL-6) (down regulate) | (Dong et al., | |
| Kolaviron | Liver inflammation | Primary biliary cirrhosis | COX-2 and iNOS | Inflammatory mediators | Inhibition | NF-κB and AP-1 (downregulation) | (Adaramoye and Lawal, |
| Liquiritigenin | Hepatic failure | Liver cirrhosis and hepatocellular carcinoma | PGC-1α, ND1, and Bcl-x | Metastasis mediators | Upregulation | Apoptosis (downregulate) | (Yu et al., |
| Liver cirrhosis and hepatocellular carcinoma | AMPK | Activation | FXR (promote expression) | (Teng et al., | |||
| Luteolin | Liver injury | Fatty liver development | SREBP-1c | Transcriptional factors | Activation | Cholesterol biosynthesis (activation) | (Seydi et al., |
| Hepatic steatosis | AMPK | Energy sensor | Activation | ATP-producing catabolic pathways | (Lee et al., | ||
| , Such as FA oxidation(activation) | (Kwon and Choi, | ||||||
| Liver cirrhosis and hepatocellular carcinoma | iNOS | Inflammatory mediators | Downregulation | NF-Kβ (down regulate) | (Jung et al., | ||
| Hepatic diseases | Hepatic fibrosis | AKT, mTOR and p70S6K | Energy sensor | Activation | TGFβ1-simulated phosphorylation of AKT(downregulate0 | (Domitrović et al., | |
| Morin | Microsomal lipid peroxidation | Fatty liver disease | COX-2 and iNOS | Inflammatory mediators | Inhibition | NF-κB (downregulation) | (Fang et al., |
| Naringenin | HIV-1/HCV co-infective liver disease | HCV-mediated hepatocellular | ACSL4, GNMT, IFI27, and miR122 | Downregulation | NF-Kβ (down regulate) | (Jain et al., | |
| Carcinoma (HCC) | TNF-α (down regulate) | (Hernández-Aquino and Muriel, | |||||
| Nobiletin | Chronic inflammatory liver disease | Liver cancer | PPARα and PGC1α | Inhibiting adhesion, | (He et al., | ||
| Chronic inflammatory liver disease | Liver cancer | ERK and PI3K/Akt | Metastasis mediators | Invasion, and migration | iNOS and COX-2, TNF-α (down regulate) | (Yuk et al., | |
| Prunetin | Lipid accumulation in the liver | Hyperlipidemia | AMPK | Metastasis mediators | activation | HMG-CoA R (inactivates) | (Wei et al., |
| Adipogenesis in the liver | Fatty liver disease | PPARγ, C/EBPα, SREBP, aP2, | Adipogenic genes | Inhibition | LDLR (promote expression) | (Chen et al., | |
| LPL adiponectin, and leptin | (Zhang et al., | ||||||
| Adipogenesis in the liver | Fatty liver disease | SREBP, PPARγ, LXR, and HMG-CoA | Lipid Metabolism-related genes | Suppressed | LDLR (promote expression) | (Walle, | |
| Adipogenesis in the liver | Fatty liver disease | Adipor1, adipoR2 | Adiponectin receptors | Induction | AMPK induction | (Wei et al., | |
| Quercetin | iNOS, COX-2 and CRP protein level | Inflammatory mediators | Downregulation | NF-Kβ (down regulate) | (Gupta et al., | ||
| Rutin | Hepatic diseases | Hepatocarcinoma | PPARα, AMPK activity, | Metastasis mediators | Downregulation | SREBP-1(down regulate) | (Pan et al., |
| Fatty liver disease | |||||||
| Obesity | |||||||
| Hyperlipidemia | |||||||
| Hepatic diseases | Hepatocarcinoma | p53 and CYP 2E1 | Reactive metabolic | Downregulation | ROS (down regulate) | (Mansour et al., | |
| Fatty liver disease | Trichloromethyl radicals | ||||||
| Liver cirrhosis | Trichloromethyl radicals | ||||||
| Silibin | Microsomal lipid peroxidation | Fatty liver disease | COX-2 and iNOS | Inflammatory mediators | Inhibition | NF-κB (downregulation) | (Yu and Ren, |
| Silymarin | Hepatic centrilobular necrosis | Paracetamol toxicity | Glutathione reductase (GSH) | Antioxidant enzymes | Increase | Microsomal ethanol-oxidizing system(increase) | (Lieber et al., |
| Steatohepatitis, hepatic fibrosis | (Boari et al., | ||||||
| Steatosis | Chronic hepatitis C | COX-2 and iNOS | Inflammatory mediators | Inhibition | NF-κB and AP-1 (downregulation) | (Saller et al., | |
| Tangeretin | Chronic inflammatory liver disease | Primary biliary cirrhosis | Pregnane X Receptor(PXR) | Nuclear receptor gene | Activation | NF-κβ (down regulate) | (Di Carlo et al., |
| Liver fibrosis | TNF-α (down regulate) | (Fracanzani et al., | |||||
| Tricin | Liver inflammation | Liver cirrhosis | ERK1/2 and Akt | Downstream signaling molecules | Supress | Blocking cell cycle progression | (Seki et al., |
| Hepatic diseases | Hepatocellular carcinoma | (PDGF)-BB | Platelet-derived growth factor | Inhibition | Blocking cell cycle progression | (Malvicini et al., |